Virus DNX2401 and Temozolomide in Recurrent Glioblastoma

Glioblastoma Multiforme Clinical Trial

— D24GBM  

Official title:

Phase I Trial of Combination of DNX-2401 (Formerly Named Delta-24-RGD) Oncolytic Adenovirus With a Short Course of Temozolomide for Treatment of Glioblastoma at First Recurrent

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01956734
• Other study ID #: D24GBM EudraCT: 2011-005935-21
• Status: Completed
• Phase: Phase 1
• First received: September 27, 2013
• Last updated: October 23, 2017
• Start date: September 2013
• Est. completion date: March 2017

Study information

• Verified date: June 2017
• Source: Clinica Universidad de Navarra, Universidad de Navarra
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Phase I trial, unicentric, uncontrolled. Intratumoral injection or intramural (into the resected tumor cavity) of DNX2401 into brain tissue will be followed by up to two 28 - day cycles of oral temozolomide (TMZ) in schedule of 7 days on/7 days off to evaluate safety of the combination. Completion of two full cycles of TMZ will be dependent upon tolerance and toxicity.

The rationale in using the virus with chemotherapy begins with the lessons learned in many clinical trials in glioblastoma (GBM) about both the great difficulty of treating this disease with monotherapy and the limitations of the therapeutic virus. The best clinical results in recent years have been achieved with combinations of multiple therapeutics efforts, including, maximum resection and chemotherapy, immunotherapy and targeted therapies.

There are very strong preclinical data about the synergy of DNX-2401 and TMZ proposed in our trial design. The dose-dense schemes of TMZ like the one we will use, have been developed with the aim to saturate o6-methylguanine-DNA-methyltransferase (MGMT). The published results to date have shown reasonable toxicity albeit with modest efficacy' these schemes are now in phase III trials. In addition, autophagy triggered by TMZ could help viral replication in the tumor cells 11.

The last argument in favor of this virus + TMZ combination is the proved efficacy in killing GBM tumor stem cells. In vitro and animals models have shown this combination is much more effective that any of the treatments alone against GBM stem cells and the tumors derived from them.

Description:

DNX2401 will be injected after stereotactic biopsy reveals intraoperative pathology confirming the presence of recurrent glioblastoma. The injection will be either intratumoral or intramural with injections throughout the post-resection cavity.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 31
• Est. completion date: March 2017
• Est. primary completion date: December 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion criteria:

• Patients willing and able to give informed consent and willing to comply with all the protocol procedures.

• Patient must be, in the investigator opinion, able to comply with all the protocol procedures.

• Age 18-75 years.

• Negative pregnant test in case of fertile women.

• Patient diagnosed GBM in first recurrence after radiotherapy and TMZ. Must have completed at least radiotherapy and one TMZ cycle afterwards.

• Intraoperative histological verification of recurrence is needed to confirm inclusion.

• Karnofsky Performance Status = 70 before inclusion

• Lesion considered by the investigator to be resectable or accessible for stereotactic biopsy. Lesion location will allow injection without entrance of virus in the ventricular system.

• Last TMZ cycle must have been finished at least 4 weeks before entry in the study.

• Must have adequate renal, bone marrow and liver function.

Exclusion criteria:

• Severe infections or intercurrent medical conditions including, but not limited to, severe renal, hepatic, heart or bone marrow failure, that, on investigator´s criteria, do not allow the inclusion.

• Participation on another clinical trial in the previous 30 days.

• Previous hypersensitivity to temozolomide or any associated components. Previous serious toxicity to temozolomide.

• Subjects with immunodeficiency, autoimmune conditions or active hepatitis.

• Any medical or psychological condition that might interfere with the subject's ability to participate or give informed consent.

• Tumor with multiple locations, unless all the lesions are considered resectable, or all the lesions except one can be resected, and the last one can be injected; diffuse subependymal spreading or location that would need injection through ventricle.

• Current diagnosis of other cancer except in situ cervical cancer, basal or squamous cell carcinoma of the skin. Patients with a history of another cancer remain eligible if they are cancer free for at least three years.

• Pregnant or breast-feeding females will be excluded, due to the risk for the fetal development of a recombinant virus containing genes related to cellular growth and differentiation.

• Severe bone marrow hypoplasia.

• Aspartate aminotransferase (AST) or Alanine aminotransferase (ALT) > 3 times over normal laboratory level.

Related Conditions & MeSH terms

• Glioblastoma
• Glioblastoma Multiforme
• Recurrent Tumor

Intervention

Procedure:
• DNX2401 and Temozolomide
Virus injection in the brain parenchyma after pathology confirmation of recurrent glioblastoma. Temozolomide oral 14 days after virus injection.

Locations

Country	Name	City	State
Spain	Clinica Universidad de Navarra	Pamplona	Navarra

Sponsors (2)

Lead Sponsor	Collaborator
Clinica Universidad de Navarra, Universidad de Navarra	DNAtrix, Inc.

Country where clinical trial is conducted

Spain, 

References & Publications (4)

Alonso MM, Gomez-Manzano C, Bekele BN, Yung WK, Fueyo J. Adenovirus-based strategies overcome temozolomide resistance by silencing the O6-methylguanine-DNA methyltransferase promoter. Cancer Res. 2007 Dec 15;67(24):11499-504. — View Citation

Fueyo J, Gomez-Manzano C, Alemany R, Lee PS, McDonnell TJ, Mitlianga P, Shi YX, Levin VA, Yung WK, Kyritsis AP. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene. 2000 Jan 6;19(1):2-12. Erratum in: Oncogene 2000 Oct 12;19(43):5038. — View Citation

Jiang H, Alonso MM, Gomez-Manzano C, Piao Y, Fueyo J. Oncolytic viruses and DNA-repair machinery: overcoming chemoresistance of gliomas. Expert Rev Anticancer Ther. 2006 Nov;6(11):1585-92. Review. — View Citation

Jiang H, Gomez-Manzano C, Lang FF, Alemany R, Fueyo J. Oncolytic adenovirus: preclinical and clinical studies in patients with human malignant gliomas. Curr Gene Ther. 2009 Oct;9(5):422-7. Review. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participans with adverse events	Tolerance of the combination of DNX-2401 and temozolomide will be evaluated through neurological and hematological status. Any toxicity will be graded according to the National Cancer Institute Common Toxicity Criteria (NCI-CTCAE) version 4.03.	3 months
Secondary	Efficacy of the combination: PFS6 and OS12	To determine, using the Revised Assessment in Neuro-Oncology (RANO) criteria, time to disease progression, progression-free survival at 6 months (PFS6), median progression-free survival, overall survival at 12 months (OS12) and median overall survival following intratumoral or intramural injection of DNX-2401 and two cycles of temozolomide	12 months
Secondary	Tumor response	To assess tumor response using RANO criteria	12 months
Secondary	Quality of life	To measure quality of life (QoL) baseline assessment and any changes over time	18 months
Secondary	Biological response	To determine immunogenicity, biomarkers and tumor genetics	3 months

External Links

•   Hospital where the clinical trial is performed